search
Adreno
Trends
- 1EU approves first drug for cerebral adrenoleukodystrophy▼European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease
The European Commission has granted marketing authorization for NEZGLYAL (leriglitazone), making it the first pharmacological treatment approved for cerebral adrenoleukodystrophy, a rare and rapidly progressive neurodegenerative disease that primarily affects young boys. Until now, care options for cALD were limited mainly to stem cell transplantation in eligible patients. The approval is being highlighted as a significant milestone for families affected by the rare disease and for rare-disease drug development in Europe.
- 2
A detailed technical analysis of Qualcomm's Adreno X2 GPU, the graphics processor in its Snapdragon X2 PC chips, has been published by the hardware analysis site Chips and Cheese. The piece examines the architecture in depth, and the topic is drawing attention among chip enthusiasts and developers following Qualcomm's latest Windows-on-ARM push.
- 3Qualcomm expands open-source Linux graphics driver work▼Qualcomm Continues Doing More For Their Open-Source Linux Graphics Drivers
Qualcomm is continuing to invest in its open-source graphics drivers for Linux, with new development efforts reported for its Adreno GPU support in the kernel's DRM driver stack. This forms part of the company's broader push to improve upstream Linux support for its chips, a shift welcomed by developers and users running Linux on Qualcomm-powered devices such as laptops and phones.